Optimal Management of Clinical Stage I Nonseminoma: New Data for Patients to Consider
Menée sur 1 226 patients atteints d'un cancer du testicule non-séminomateux de stade I traité par orchidectomie, cette étude évalue, du point de vue du taux de récidive à 5 ans et du taux de survie spécifique à 15 ans, l'intérêt d'un programme de surveillance médicale du patient après traitement
The optimal management of clinical stage I (CSI) nonseminomatous germ cell tumors (NSGCT) is still controversial. The obvious explanation is that either early definitive treatment or watch ful waiting and chemotherapy at the time of disease recurrence cures nearly 100% of patients. There are no trial data that provide robust evidence for the superiority of one approach over the other. As a result, treatment choices have been guided by institutional or national consensus rather than based on evidence...
Journal of Clinical Oncology , éditorial en libre accès, 2014